227 related articles for article (PubMed ID: 18722778)
1. Tetrahydropyridine-4-carboxamides as novel, potent transient receptor potential vanilloid 1 (TRPV1) antagonists.
Brown BS; Keddy R; Zheng GZ; Schmidt RG; Koenig JR; McDonald HA; Bianchi BR; Honore P; Jarvis MF; Surowy CS; Polakowski JS; Marsh KC; Faltynek CR; Lee CH
Bioorg Med Chem; 2008 Sep; 16(18):8516-25. PubMed ID: 18722778
[TBL] [Abstract][Full Text] [Related]
2. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists.
Cui M; Honore P; Zhong C; Gauvin D; Mikusa J; Hernandez G; Chandran P; Gomtsyan A; Brown B; Bayburt EK; Marsh K; Bianchi B; McDonald H; Niforatos W; Neelands TR; Moreland RB; Decker MW; Lee CH; Sullivan JP; Faltynek CR
J Neurosci; 2006 Sep; 26(37):9385-93. PubMed ID: 16971522
[TBL] [Abstract][Full Text] [Related]
3. Actions of two naturally occurring saturated N-acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels.
De Petrocellis L; Chu CJ; Moriello AS; Kellner JC; Walker JM; Di Marzo V
Br J Pharmacol; 2004 Sep; 143(2):251-6. PubMed ID: 15289293
[TBL] [Abstract][Full Text] [Related]
4. Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity.
García-Martínez C; Fernández-Carvajal A; Valenzuela B; Gomis A; Van Den Nest W; Ferroni S; Carreño C; Belmonte C; Ferrer-Montiel A
J Pain; 2006 Oct; 7(10):735-46. PubMed ID: 17018334
[TBL] [Abstract][Full Text] [Related]
5. Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles.
Ognyanov VI; Balan C; Bannon AW; Bo Y; Dominguez C; Fotsch C; Gore VK; Klionsky L; Ma VV; Qian YX; Tamir R; Wang X; Xi N; Xu S; Zhu D; Gavva NR; Treanor JJ; Norman MH
J Med Chem; 2006 Jun; 49(12):3719-42. PubMed ID: 16759115
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists.
Blum CA; Caldwell T; Zheng X; Bakthavatchalam R; Capitosti S; Brielmann H; De Lombaert S; Kershaw MT; Matson D; Krause JE; Cortright D; Crandall M; Martin WJ; Murphy BA; Boyce S; Jones AB; Mason G; Rycroft W; Perrett H; Conley R; Burnaby-Davies N; Chenard BL; Hodgetts KJ
J Med Chem; 2010 Apr; 53(8):3330-48. PubMed ID: 20307063
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of (3S)-3-(hydroxymethyl)-4-(5-methylpyridin-2-yl)-N-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide (JTS-653), a novel transient receptor potential vanilloid 1 antagonist.
Kitagawa Y; Miyai A; Usui K; Hamada Y; Deai K; Wada M; Koga Y; Sakata M; Hayashi M; Tominaga M; Matsushita M
J Pharmacol Exp Ther; 2012 Aug; 342(2):520-8. PubMed ID: 22588258
[TBL] [Abstract][Full Text] [Related]
8. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats.
Lehto SG; Tamir R; Deng H; Klionsky L; Kuang R; Le A; Lee D; Louis JC; Magal E; Manning BH; Rubino J; Surapaneni S; Tamayo N; Wang T; Wang J; Wang J; Wang W; Youngblood B; Zhang M; Zhu D; Norman MH; Gavva NR
J Pharmacol Exp Ther; 2008 Jul; 326(1):218-29. PubMed ID: 18420600
[TBL] [Abstract][Full Text] [Related]
9. 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent transient receptor potential vanilloid 1 (TRPV1) antagonists: structure-activity relationships of 2-amino derivatives in the N-(6-trifluoromethylpyridin-3-ylmethyl) C-region.
Kim MS; Ryu H; Kang DW; Cho SH; Seo S; Park YS; Kim MY; Kwak EJ; Kim YS; Bhondwe RS; Kim HS; Park SG; Son K; Choi S; DeAndrea-Lazarus IA; Pearce LV; Blumberg PM; Frank R; Bahrenberg G; Stockhausen H; Kögel BY; Schiene K; Christoph T; Lee J
J Med Chem; 2012 Oct; 55(19):8392-408. PubMed ID: 22957803
[TBL] [Abstract][Full Text] [Related]
10. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia.
Honore P; Chandran P; Hernandez G; Gauvin DM; Mikusa JP; Zhong C; Joshi SK; Ghilardi JR; Sevcik MA; Fryer RM; Segreti JA; Banfor PN; Marsh K; Neelands T; Bayburt E; Daanen JF; Gomtsyan A; Lee CH; Kort ME; Reilly RM; Surowy CS; Kym PR; Mantyh PW; Sullivan JP; Jarvis MF; Faltynek CR
Pain; 2009 Mar; 142(1-2):27-35. PubMed ID: 19135797
[TBL] [Abstract][Full Text] [Related]
11. Differential involvement of TRPV1 receptors at the central and peripheral nerves in CFA-induced mechanical and thermal hyperalgesia.
Kanai Y; Hara T; Imai A; Sakakibara A
J Pharm Pharmacol; 2007 May; 59(5):733-8. PubMed ID: 17524240
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of peripherally restricted transient receptor potential vanilloid 1 (TRPV1) antagonists.
Tamayo N; Liao H; Stec MM; Wang X; Chakrabarti P; Retz D; Doherty EM; Surapaneni S; Tamir R; Bannon AW; Gavva NR; Norman MH
J Med Chem; 2008 May; 51(9):2744-57. PubMed ID: 18386885
[TBL] [Abstract][Full Text] [Related]
13. Anti-nociceptive and desensitizing effects of olvanil on capsaicin-induced thermal hyperalgesia in the rat.
Alsalem M; Millns P; Altarifi A; El-Salem K; Chapman V; Kendall DA
BMC Pharmacol Toxicol; 2016 Jul; 17(1):31. PubMed ID: 27439609
[TBL] [Abstract][Full Text] [Related]
14. Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect.
Watabiki T; Kiso T; Kuramochi T; Yonezawa K; Tsuji N; Kohara A; Kakimoto S; Aoki T; Matsuoka N
J Pharmacol Exp Ther; 2011 Mar; 336(3):743-50. PubMed ID: 21098091
[TBL] [Abstract][Full Text] [Related]
15. Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate.
Doherty EM; Fotsch C; Bannon AW; Bo Y; Chen N; Dominguez C; Falsey J; Gavva NR; Katon J; Nixey T; Ognyanov VI; Pettus L; Rzasa RM; Stec M; Surapaneni S; Tamir R; Zhu J; Treanor JJ; Norman MH
J Med Chem; 2007 Jul; 50(15):3515-27. PubMed ID: 17585750
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology of modality-specific transient receptor potential vanilloid-1 antagonists that do not alter body temperature.
Reilly RM; McDonald HA; Puttfarcken PS; Joshi SK; Lewis L; Pai M; Franklin PH; Segreti JA; Neelands TR; Han P; Chen J; Mantyh PW; Ghilardi JR; Turner TM; Voight EA; Daanen JF; Schmidt RG; Gomtsyan A; Kort ME; Faltynek CR; Kym PR
J Pharmacol Exp Ther; 2012 Aug; 342(2):416-28. PubMed ID: 22570364
[TBL] [Abstract][Full Text] [Related]
17. Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor.
Gunthorpe MJ; Hannan SL; Smart D; Jerman JC; Arpino S; Smith GD; Brough S; Wright J; Egerton J; Lappin SC; Holland VA; Winborn K; Thompson M; Rami HK; Randall A; Davis JB
J Pharmacol Exp Ther; 2007 Jun; 321(3):1183-92. PubMed ID: 17392405
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship studies and discovery of a potent transient receptor potential vanilloid (TRPV1) antagonist 4-[3-chloro-5-[(1S)-1,2-dihydroxyethyl]-2-pyridyl]-N-[5-(trifluoromethyl)-2-pyridyl]-3,6-dihydro-2H-pyridine-1-carboxamide (V116517) as a clinical candidate for pain management.
Tafesse L; Kanemasa T; Kurose N; Yu J; Asaki T; Wu G; Iwamoto Y; Yamaguchi Y; Ni C; Engel J; Tsuno N; Patel A; Zhou X; Shintani T; Brown K; Hasegawa T; Shet M; Iso Y; Kato A; Kyle DJ
J Med Chem; 2014 Aug; 57(15):6781-94. PubMed ID: 25057800
[TBL] [Abstract][Full Text] [Related]
19. Increased depressor response to N-arachidonoyl-dopamine during high salt intake: role of the TRPV1 receptor.
Wang Y; Wang DH
J Hypertens; 2007 Dec; 25(12):2426-33. PubMed ID: 17984664
[TBL] [Abstract][Full Text] [Related]
20. Novel piperazine urea derivatives as highly potent transient receptor potential vanilloid 1 (TRPV1) antagonists.
Hu J; Gao M; Zhang Y; Wang Y; Qiao Z; Zhang W; Wang Q; Yan L; Qian H
Bioorg Chem; 2021 Oct; 115():105229. PubMed ID: 34364049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
